Subscribe To Our Free Newsletter |
Alembic Pharmaceuticals receives USFDA final approval for Albendazole Tablets
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Albendazole Tablets USP, 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), LAlbenza Tablets, 200 mg, of Impax Laboratories, Inc. (Impax).